TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion

Friday, February 03, 2023

Skye Bioscience, Inc., a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has entered into an agreement with Lexitas Pharma Services, Inc. ("Lexitas"), a leading full-service ophthalmic-focused contract research organization ("CRO") for its Phase 2a study for glaucoma and hypertension. This study is planned to begin in the US in the first half of 2023.

After reviewing various options, Skye retained Lexitas based on their extensive experience and expertise within ophthalmology. Since 2011, Lexitas has provided end-to-end clinical trial and medical strategy services, focused on ophthalmic product development. They have significant expertise in both anterior and posterior segments of ophthalmology, including glaucoma.

"We have a high level of confidence in Lexitas' expertise to support our Phase 2a study in the United States," said Tu Diep, Chief Development Officer of Skye. "Lexitas' strong relationships with glaucoma investigators, proven operational expertise and a commitment to high-quality data, they are the ideal partner for this important trial ."

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit